About this trial
The purpose of this study is to examine the rate and concentration of amino acid absorption after a three-week pattern of milk protein supplementation with and without the addition of a single strain probiotic.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Participants will be male or female between the ages of 18-35 years;
Participants have not been consuming any nutritional supplements for the preceding 6-week period;
Participants have not been consuming any ergogenic aids for the preceding 6-week period;
Participant has provided written and dated informed consent to participate in the study;
Disqualifiers
Participant is allergic to any ingredient in the nutritional supplement or placebo;
Participant is not pregnant or trying to become pregnant, nor breast feeding;
Participant reports any unusual adverse events associated with this study that in consultation with the study investigators or their doctor recommends removal from the study;
Participant currently ingests nicotine or has quit within the last 6 months;
Trial design
Crossover
Treatments tested in this trial
Single Strain Probiotic + Milk Protein
Dietary supplement• Both conditions matched flavor, color, and serving size
Placebo + Milk Protein
Dietary supplement• Both conditions matched flavor, color, and serving size
Treatment groups
Trial outcomes
Primary outcomes
Rate of amino acid absorption
To determine if the addition of a probiotic to milk protein ingestion changes the rate (in minutes) to which amino acids are absorbed into our bloodstream.
Concentration of amino acid absorption
To determine if the addition of a probiotic to milk protein ingestion changes the extent (concentration in millimoles/Liter) to which amino acids are absorbed into our bloodstream.
Secondary outcomes
Comprehensive metabolic panel
Comprehensive metabolic panel will be assessed pre vs. post supplementation across the two treatment groups for blood safety data. • All measures are assessed by blood or serum assay analysis
Blood CBC panel
Blood CBC panel will be assessed pre vs. post supplementation across the two treatment groups for blood safety data. • All measures are assessed by blood or serum assay analysis
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The Archer-Daniels-Midland Company
Lead sponsor
University of Mary Hardin-Baylor
Collaborator
This trial is not recruiting at the moment. You can still explore other options: